RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints
China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...
Drug
AstraZeneca’s Trixeo Aerosphere Wins UK Approval for COPD
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced this week that it has received marketing...
Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial
Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...
Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...
Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...
Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...
CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...
CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG
Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...
Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development
China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...
InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...
IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma
China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...
Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...
NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...
J&J’s Tremfya Approved for Ulcerative Colitis in China
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...
Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...
Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...
Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...